BrECADD versus BEACOPP in advanced HL: a German Hodgkin Study Group investigation 

Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses a German study comparing the BrECADD regimen (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) to BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) for advanced Hodgkin lymphoma (HL). The study found BrECADD to have encouraging efficacy, and Dr Svoboda is excited to see how this regimen will integrate into the US treatment landscape. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.